Investment Securities (Tables)

3 Months Ended

Oct. 31, 2019

Notes to Financial Statements

Marketable Securities

66,667 Common Shares of Entest Group, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended October 31 2019		Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019
$	1,133	$	1,426	$	293	$	293

29,076,665 Common Shares of Regen Biopharma, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended October 31 2019		Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019
$	17,446	$	23,261	$	5,815	$	5,815

290,766 Series A Preferred Shares of Regen Biopharma,  Inc.
	Basis	Fair Value		Change in Fair Value for the Quarter ended October 31 2019			Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019
$	29,076	8,141	$	(20,935	)	$	(20,935	)

4411 Common Shares of Zander Therapeutics, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended October 31 2019			Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019
$	254	$	71	$	(184	)	$	(184	)

5000 Series M Preferred Shares of Zander Therapeutics, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended October 31 2019			Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019
$	289	$	80	$	(209	)	$	(209	)

8,333 Series B Preferred Shares of Entest Group, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended October 31 2019		Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019
$	0	$	0	$	0	$	0